VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2007 | 2.23 Million USD | 183.84% |
| 2006 | -2.66 Million USD | 53.68% |
| 2005 | -5.75 Million USD | -87.79% |
| 2004 | -3.06 Million USD | -365.1% |
| 2003 | -659.11 Thousand USD | 79.47% |
| 2002 | -3.21 Million USD | -4530.51% |
| 2001 | 72.47 Thousand USD | 96.76% |
| 2000 | 36.83 Thousand USD | 385.59% |
| 1999 | -12.89 Thousand USD | -127.96% |
| 1998 | 46.12 Thousand USD | 239.25% |
| 1997 | 13.59 Thousand USD | 493.55% |
| 1996 | -3455.00 USD | -110.47% |
| 1995 | 33 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2008 Q1 | -305.56 Thousand USD | -113.67% |
| 2008 Q2 | -814.47 Thousand USD | -166.55% |
| 2007 Q2 | -879.4 Thousand USD | -460.4% |
| 2007 Q3 | 93.91 Thousand USD | 110.68% |
| 2007 Q4 | 2.23 Million USD | 2280.82% |
| 2007 Q1 | -156.92 Thousand USD | 94.12% |
| 2007 FY | 2.23 Million USD | 183.84% |
| 2006 FY | -2.66 Million USD | 53.68% |
| 2006 Q1 | -3.01 Million USD | 47.6% |
| 2006 Q2 | -2.06 Million USD | 31.63% |
| 2006 Q3 | -558.5 Thousand USD | 72.92% |
| 2006 Q4 | -2.66 Million USD | -377.46% |
| 2005 Q4 | -5.75 Million USD | -2099.07% |
| 2005 Q1 | -1.48 Million USD | 51.59% |
| 2005 Q2 | -1.15 Million USD | 22.18% |
| 2005 FY | -5.75 Million USD | -87.79% |
| 2005 Q3 | -261.78 Thousand USD | 77.33% |
| 2004 Q3 | -4.05 Million USD | 22.8% |
| 2004 Q1 | -6.42 Million USD | -875.18% |
| 2004 Q4 | -3.06 Million USD | 24.49% |
| 2004 FY | -3.06 Million USD | -365.1% |
| 2004 Q2 | -5.25 Million USD | 18.19% |
| 2003 Q2 | -1.79 Million USD | 25.94% |
| 2003 FY | -659.11 Thousand USD | 79.47% |
| 2003 Q4 | -659.11 Thousand USD | 28.28% |
| 2003 Q3 | -918.99 Thousand USD | 48.68% |
| 2003 Q1 | -2.41 Million USD | 24.69% |
| 2002 Q3 | -3.19 Million USD | -10.82% |
| 2002 FY | -3.21 Million USD | -4530.51% |
| 2002 Q4 | -3.21 Million USD | -0.39% |
| 2002 Q2 | -2.88 Million USD | -6343.65% |
| 2002 Q1 | -44.79 Thousand USD | -161.8% |
| 2001 Q2 | 41.37 Thousand USD | 81.59% |
| 2001 Q3 | 54.44 Thousand USD | 31.59% |
| 2001 Q4 | 72.47 Thousand USD | 33.12% |
| 2001 FY | 72.47 Thousand USD | 96.76% |
| 2001 Q1 | 22.78 Thousand USD | -38.14% |
| 2000 Q4 | 36.83 Thousand USD | -25.57% |
| 2000 Q3 | 49.49 Thousand USD | 1.82% |
| 2000 FY | 36.83 Thousand USD | 385.59% |
| 2000 Q1 | -4276.00 USD | 0.0% |
| 2000 Q2 | 48.6 Thousand USD | 1236.76% |
| 1999 FY | -12.89 Thousand USD | -127.96% |
| 1998 FY | 46.12 Thousand USD | 239.25% |
| 1997 FY | 13.59 Thousand USD | 493.55% |
| 1996 FY | -3455.00 USD | -110.47% |
| 1995 FY | 33 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 170774.198% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 60.416% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.775% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 995.694% |
| Rebus Holdings, Inc. | 305 Thousand USD | -633.06% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 135.464% |
| Qrons Inc. | 351.42 Thousand USD | -536.215% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -259.248% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.852% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 11055.664% |
| Skye Bioscience, Inc. | -5.72 Million USD | 139.078% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 85.816% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 45.706% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -456.386% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.17% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 0.285% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -141.142% |
| Mesoblast Limited | 55.85 Million USD | 95.997% |
| Marizyme, Inc. | 18.56 Million USD | 87.959% |
| Genus plc | 190.6 Million USD | 98.827% |
| Pharming Group N.V. | 109.8 Million USD | 97.964% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -159.908% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -84.188% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -228.799% |
| ContraFect Corporation | -6.02 Million USD | 137.103% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1560.612% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -93.507% |
| IMV Inc. | 7.67 Million USD | 70.852% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 59.363% |
| MultiCell Technologies, Inc. | 90.04 USD | -2483054.154% |
| ONE Bio Corp. | 9.04 Million USD | 75.267% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 404.618% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 82.73% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -63.441% |
| Q BioMed Inc. | 4.06 Million USD | 44.93% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.682% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -121.871% |
| Biomind Labs Inc. | 711.4 Thousand USD | -214.285% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.307% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -11.826% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.542% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -521.565% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1499.262% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -11153.999% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1.537% |
| GB Sciences, Inc. | 1.74 Million USD | -27.958% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1316.528% |
| HST Global, Inc. | 96.79 Thousand USD | -2209.911% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -984.213% |
| Halberd Corporation | 144.72 Thousand USD | -1444.926% |
| Enzolytics Inc. | 981.65 Thousand USD | -127.761% |
| Agentix Corp. | 37.63 Thousand USD | -5841.463% |
| Resverlogix Corp. | 6.45 Million USD | 65.341% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 432.175% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.11% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.756% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 68.38% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 17.455% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 125.292% |
| AVAX Technologies, Inc. | -5.9 Million USD | 137.875% |
| Zenith Capital Corp. | 10.06 Thousand USD | -22116.137% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.211% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1015.507% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 6.295% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1259.094% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 12305.656% |
| Kadimastem Ltd | -253.1 Thousand USD | 983.372% |
| Helix BioMedix, Inc. | -2.57 Million USD | 186.996% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 88.973% |
| BioStem Technologies, Inc. | 4.47 Million USD | 50.004% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1010.95% |
| LadRx Corporation | -2.03 Million USD | 209.79% |
| Cell Source, Inc. | 9.23 Million USD | 75.782% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -252.007% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -252.007% |
| NovAccess Global Inc. | 2.17 Million USD | -2.633% |
| Affymax, Inc. | -5.59 Million USD | 139.947% |
| Itoco Inc. | 228.3 Thousand USD | -879.318% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1544.127% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 54.895% |
| Mobile Lads Corp. | 484.23 Thousand USD | -361.727% |
| CytoDyn Inc. | 20.26 Million USD | 88.965% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 345669.088% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 24223.327% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 70.986% |
| SYBLEU INC | 473.71 Thousand USD | -371.979% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 49.836% |
| International Stem Cell Corporation | 2.59 Million USD | 13.674% |
| Bioxytran, Inc. | 1.89 Million USD | -17.743% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3482.318% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -2.519% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 34.891% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 73.859% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -189.388% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 278.867% |
| Neutra Corp. | 52.18 Thousand USD | -4184.27% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 189.829% |
| PureTech Health plc | -167.19 Million USD | 101.337% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1012.927% |
| IXICO plc | -4.44 Million USD | 150.305% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 83.086% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.924% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Cellectis S.A. | -43.81 Million USD | 105.102% |